China-based online pharmacy 111 Inc. (NASDAQ: YI) has announced the appointment of its Senior Finance Executive, Mr. Yang “Luke” Chen, as a new director. This follows the resignation of Dr. Leon Lian Yong Chen from the company’s board due to personal reasons, effective immediately.
Dr. Lian Yong Chen’s Background and Contributions
Dr. Lian Yong Chen, with over 20 years of experience in the life science industry, has made significant contributions to 111 Inc. since joining the board in May 2019. He is the founder of Frontline Investment and has served as a partner at Fidelity Asia Growth. Dr. Chen has led major investments in China’s biopharmaceutical sector, including CITIC Pharmaceutical, Ltd., Shanghai Hile Bio-Technology Co., Ltd., Hua Medicine, Innovent Biologics, Inc., Adagene Inc., and others.
Mr. Yang “Luke” Chen’s Qualifications and Experience
Mr. Yang “Luke” Chen, a graduate of Shanghai University of Finance and Economics, furthered his education with an EMBA degree from the Olin Business School at the University of Washington. He was appointed as the Chief Financial Officer (CFO) of 111 Inc. in 2019 and now steps into the role of director, bringing his financial acumen and industry knowledge to the company’s governance.- Flcube.com
